Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain investigational. Overall, the ATALANTA-1 data reinforce that optimized autologous ...
ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular ...
Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...
This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...
Avantor Inc. (NYSE:AVTR) is one of the best large cap stocks to buy under $20. On October 15, Avantor announced a partnership with BlueWhale Bio, which is a commercial-stage company that transforms ...
Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results